Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response <i>In vitro</i> and <i>In vivo</i>

Abstract

The timing of IGF1R inhibition affects responses to chemotherapy. The optimal sequence was doxorubicin followed by anti-IGF1R antibody, whereas the opposite sequence inhibited doxorubicin effects. Thus, the dose and sequencing of anti-IGF1R therapies should be considered in the design of future clinical trials.